Form 4 for KRYS Krystal Biotech, Inc.
Accepted 2026-05-27 17:17:56 ET · period of report 2026-05-26 · accession 0002114900-26-000006 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-05-27 17:17 | 2026-05-26 | KRYS | Thomas John Charles | EVP, GC | S - Sale | $302.03 | -642 | 0 | -100% | -$193.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-05-26 | S | D | 642 | $302.03 | 0 | D | — | — | (F1) The sales reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 23, 2026. The Rule 10b5-1 trading plan will terminate on December 31, 2026, or earlier in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan. |